Is CGEN or CLLS more undervalued in 2026?

CirclFi compares Compugen Ltd. (CGEN) and Cellectis S.A. (CLLS) using 13 institutional-grade valuation models. CGEN has a Quality of Company score of 9.0/10 while CLLS scores 2.5/10.

Which is a better buy — CGEN or CLLS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CGEN and CLLS valuations compare?

CGEN at $2.63 and CLLS at $3.52 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CGEN vs CLLS Valuation Comparison 2026 — Intrinsic Value Analysis

CGEN

Biological Products, (No Diagnostic Substances)

Compugen Ltd.

Quality

9.0

out of 10

Value Trap

SAFE

Price

$2.63

Last close

Models

12/13

Active

CLLS

Biological Products, (No Diagnostic Substances)

Cellectis S.A.

Quality

2.5

out of 10

Value Trap

SAFE

Price

$3.52

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	CGEN Fair Value	CGEN Upside	CLLS Fair Value	CLLS Upside
Bayesian DCF	Intrinsic	$4.07	+54.7%	$0.93	-73.7%
Earnings Power Value	Intrinsic	$3.30	+25.6%	$1.52	-61.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CGEN vs CLLS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CGEN vs CLLS — Which Stock Is More Undervalued?

CGEN scores higher with a 9.0/10 quality rating vs CLLS's 2.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Compugen Ltd. (CGEN) and Cellectis S.A. (CLLS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CGEN currently trades at $2.63 with a QOC of 9.0/10, while CLLS trades at $3.52 with a QOC of 2.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).